SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Creative Media & Community Trust Corp. is a real estate investment trust that seeks to own, operate, and develop premier multifamily and creative office assets in vibrant and emerging communities throughout the United States. It operates through the following segments: Office, Hotel, and Lending. The Office segment consists of the rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment involves the operation of hotel properties. The Lending segment focuses on loans to small businesses. The company was founded in 1993 and is headquartered in Dallas, TX.

Creative Media & Community Trust

CMCT is trending due to news of a lending division sale, sparking interest in its micro float and potential for a short squeeze. While some traders express optimism for gains, others cite concerns over the company's debt, leading to discussions about risk management.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending following a strong earnings report and increased full-year guidance, with community members highlighting the potential for significant revenue growth and a rebrand to CorMedix Therapeutics. The community is actively discussing the impact of these results, and a conference call is scheduled where further details may be revealed. Broader discussions include the company's strategic investments and potential for shareholder value.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle ($CRCL) is trending as the stock reacts to strong earnings and a growing USDC circulation, with some community members discussing the potential for Cathie Wood to increase her position. Despite positive financial results, the stock initially experienced a dip, leading to debates about market irrationality and future price movement with the lockup period expiring soon.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

News of Luckin Coffee's potential U.S. relisting is generating buzz, with community members speculating about the timeline and impact on the stock. Discussions also involve the company's expansion plans and potential competition with Starbucks. Despite some skepticism, many longs are optimistic about Luckin's growth and future prospects.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

JMIA is trending following recent earnings, with community members noting a widened loss but increased revenue. Discussions are centered on whether to buy the dip, with some expressing concerns about liquidity while others highlight positive growth and long-term profitability targets. Upcoming investor day is also a key point of focus for potential catalysts.

Leifras Co., Ltd. Engages in sport training, event and alliance & club activity support and healthcare activities. It provides services related to the organization and operations of sports schools and sports events for children and it also operate a robust social business sector, dispatching sports coaches to meet various community needs. The company was founded by Kiyotaka Ito on August 28, 2001 and is headquartered in Tokyo, Japan.

Leifras Co Ltd - ADR

LEIFRAS Co., Ltd. American Depositary Shares

$LFS is trending due to a massive surge, with community members pointing to a potential short squeeze and comparing it to other high-flying stocks. Discussions revolve around whether this run can continue and which stock could be the 'next LFS'. Some traders attribute the move to news regarding a contract in Nagoya, while others suspect a pump and dump.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

On Holding (ONON) is trending due to positive investor sentiment following raised FY25 revenue growth outlook. The community is buzzing about the company's strong sales and potential for a short squeeze, while some debate its valuation and competition within the shoe market. The focus remains on the company's growth in Asia and overall execution.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as investors debate the stock's future following recent news and ahead of an upcoming earnings report, with some expressing concerns about cash burn and others highlighting potential catalysts like FAA certification progress and partnerships. Discussions include contrasting opinions on the company's prospects versus competitors and the impact of analyst ratings, while technical analysis and potential support/resistance levels are also being closely monitored. The community is focused on both short-term trading opportunities and the long-term vision for the eVTOL sector.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

Traders are closely watching AVXL as it approaches its EMA oral explanation, the last step before a decision on its Alzheimer's drug, blarcamesine. Community chatter revolves around the potential for conditional approval and how management addresses outstanding questions, especially concerning the drug's efficacy. Recent price action suggests heightened uncertainty, with some interpreting the need for an oral explanation as a sign of regulatory scrutiny, while others remain optimistic about blarcamesine's potential benefits and market position.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending following its analyst day, where long-term growth targets were revealed, sparking optimism; the data center market is projected to reach $1 trillion by 2030. Community members are actively discussing price targets and the potential for AMD to gain market share in the AI space, with some drawing comparisons to NVDA's trajectory and others expressing skepticism.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$LCTX Still waiting for someone to logically disprove my claim that LCTX does not have an advantage over others for producing islet cells. So far, I&#39;ve gotten some insults (to be expected). I corrected a link. And some people seem to actually be taking me seriously. I am ultra long $SANA, don&#39;t care about LCTX at all and I think LCTX has 0 impact on Sana stock price. Not short or long LCTX. Worried for LCTX shareholders though. LCTX CEO is clearly making false claims and being secretive about their scale up process (which in the CEO&#39;s own words is WORSE than competitors). LCTX is giving me Theranos vibes.

$LCTX $SANA [repost with correct 1st link] I found some actual math to back up how so full of crap $LCTX is. Mind you, this is from ~1 hour of simple research by an actual bioengineer. This article here (https://www.genengnews.com/gen-edge/lineage-cell-therapeutics-makes-medicines-based-on-transplanting-differentiated-cells/#:~:text=Cells%20behave%20differently%20based%20on,scale%20poses%20some%20daunting%20challenges.%E2%80%9D) states they can make 2500 courses of RPE product per 3L bioreactor. Per this link (https://investor.lineagecell.com/static-files/0a63d555-a7d6-44a0-8e11-d5d08f65754c) page 5, 1 course is either 50k or 200k cells. Multiply by 2500, that&#39;s 125 million to 500 million cells per 3L reactor. That&#39;s crap. This presentation (https://www.youtube.com/watch?v=AjSSFOkDG6U&amp;t=1625s) @ 27:19 from lab of former Sana VP used a 3L bioreactor from PBS here https://www.pbsbiotech.com/products/pbs-3 (hey, unlike LCTX, you can actually see this company&#39;s tech!!!!! a simple fkn wheel that spins!) to make 3.3 billion islet cells. And in the LCTX press release (https://investor.lineagecell.com/news-releases/news-release-details/lineage-cell-therapeutics-initiates-cell-transplant-program-type), LCTX boasted about making hundreds of millions of islet cells, an order of magnitude less than the 3.3 billion Sana can already make and not even a full dose for T1D (~1 billion cells).

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing differentiated cell-based transplant therapies.

Lineage Cell Therapeutics Makes Medicines Based on Transplanting Differentiated Cells

Stem cell derived islets for the treatment of diabetes

PBS-3 single-use bioreactor has an 3L working volume and can be used to optimize your cell culture process.

PBS-3 | PBS Biotech | PBS Biotech

The Investor Relations website contains information about Lineage Cell Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.

Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes | Lineage Cell Therapeutics, Inc.

StockTwits Web

Lineage Cell Therapeutics Inc

Sana Biotechnology Inc

LunarPixel87

$LCTX Ultra long SANA? good luck with that. all assets are pre clinical, ripping through $50M per quarter. u are talking about LCTX ceo. Where is all the money going at Sana? and on top of that $90M in debt as a pre clinical biotech company....that is excellent stewardship of capital.

$LCTX im waiting as well. you never responded to my comment about opregan. who cares about islet cells. it is a spit in a bucket if lctx is successful or not. its very simple. if opregan gets approved we all make out huge. if not, then we loose our shirts. it has nothing to do with islet cells, that could only be icing on the cake if it ever gets to it but opregan has to happen first. u are trying to save us money and r very concerned for us and you are ultra long sana. all sana has now is guaranteed many capital raises in the future. please logically rip apart opregan so we can start there. islet cells is not a starting point and completely irrelevant in lctx investment thesis at this point

$LCTX $SANA LCTX: Proven platform for analogous cell products, but no specific islet runs yet. In Q3 2025, completed full cGMP production runs for OpRegen (retinal cells) and OPC1 (oligodendrocytes) from the same VAC system, yielding viable clinical-grade cells and supporting &quot;millions of doses.&quot; Islet program (launched Sep 2025) applies this directly, claiming feasibility for hundreds of millions of islet cells per dose, but remains in early development with no completed islet-specific runs announced.

LCTX has stronger evidence of transferable, scalable cGMP manufacturing maturity, while SANA has clinical proof of islet function (via UP421) but unproven stem cell-derived scaling. Neither has fully proven commercial-scale islet production as of November 2025; both programs are advancing rapidly toward that goal.

StockTwits For Android 

Brat

$LCTX $SANA SANA (SC451): No proven large-scale islet production. SC451 remains pre-clinical with a HIP-edited master cell bank ready for GMP, but manufacturing is outsourced to CDMOs. Clinical proof exists for precursor UP421 (HIP-modified primary islets from donors): transplanted without immunosuppression, showed survival, immune evasion, and insulin production (stable C-peptide, positive MMTT) up to 12 weeks (NEJM publication) and 6 months. 

However, UP421 uses limited donor islets (not scalable stem cell-derived), and SC451 has no reported production runs or doses manufactured at scale.

$LCTX $SANA SANA: No fully proven large-scale production to date. While the Bothell facility opened in 2024 and supported early-stage process development, there are no public reports of completed cGMP runs for clinical doses or commercial validation. The 2025 pivot to CDMOs implies internal capabilities remain unproven at scale, with reliance on partners for any near-term output.

LCTX: Proven cGMP production capabilities. In May 2025, LCTX announced successful completion of a full production run for two distinct product candidates (OpRegen for retinal disease and VAC-NC1 for neuronal support) using its cGMP cell banking system, yielding viable cells for clinical use. This was followed by initiating a Type 1 diabetes transplant program in Sep 2025, directly deploying these capabilities to produce islet-like cells at scale (addressing ~10^9 cells per patient). Q3 2025 earnings highlighted leveraging this for overcoming industry-scale challenges, confirming operational maturity.

 Still waiting for someone to logically disprove my claim that LCTX does not have an advantage over others for producing islet cells. So far, I've gotten some insults (to be expected). I corrected a link. And some people seem to actually be taking me seriously. I am ultra long 

, don't care about LCTX at all and I think LCTX has 0 impact on Sana stock price. Not short or long LCTX. Worried for LCTX shareholders though. LCTX CEO is clearly making false claims and being secretive about their scale up process (which in the CEO's own words is WORSE than competitors). LCTX is giving me Theranos vibes.

@LunarPixel87 
$LCTX Respectfully, that’s a misread of the dynamics here. The “advantage” isn’t just about making islet cells — it’s about how they’re made, who they’re made with, and what validation sits behind the process.

Lineage isn’t trying to out-market SANA or mimic their platform. Their competitive edge lies in differentiation consistency, cost efficiency, and regulatory readiness — all of which come from years of direct GMP manufacturing experience with OpRegen. That’s real-world scale-up under FDA oversight, not a preclinical slide deck.

Calling it “Theranos vibes” ignores the fact that Roche — one of the most selective partners in biotech — has committed milestone capital and manufacturing collaboration. That’s a tangible external validation few early cell therapy developers can claim.

 • Roche partnership = institutional validation.
 • CIRM finalist + scale-up progress = operational credibility.
 • Islet cells = pipeline optionality built on proven manufacturing IP.

StockTwits for iOS

 Respectfully, that’s a misread of the dynamics here. The “advantage” isn’t just about making islet cells — it’s about how they’re made, who they’re made with, and what validation sits behind the process.

Lineage isn’t trying to out-market SANA or mimic their platform. Their competitive edge lies in differentiation consistency, cost efficiency, and regulatory readiness — all of which come from years of direct GMP manufacturing experience with OpRegen. That’s real-world scale-up under FDA oversight, not a preclinical slide deck.

Calling it “Theranos vibes” ignores the fact that Roche — one of the most selective partners in biotech — has committed milestone capital and manufacturing collaboration. That’s a tangible external validation few early cell therapy developers can claim.

 • Roche partnership = institutional validation.
 • CIRM finalist + scale-up progress = operational credibility.
 • Islet cells = pipeline optionality built on proven manufacturing IP.

Rob Thompson

@z06forum their IP is nowhere close to proven to be able to scale islets sufficiently. They can do cGMP manufacturing, I believe that, so can a lot of other people though. The scale that OpRegen requires is insignificant compared to what is required for islets. Scaling at the size required for OpRegen does not mean they are automatically the best suited for islet scale up

 their IP is nowhere close to proven to be able to scale islets sufficiently. They can do cGMP manufacturing, I believe that, so can a lot of other people though. The scale that OpRegen requires is insignificant compared to what is required for islets. Scaling at the size required for OpRegen does not mean they are automatically the best suited for islet scale up

@LunarPixel87 
Fair point — islet scale-up is an entirely different order of magnitude, no one’s disputing that. But you’re overlooking why $LCTX is positioned better than most to approach that challenge.

The key advantage isn’t just existing GMP capacity — it’s a validated process-development platform that’s already been audited, scaled, and transferred under a global pharma partnership. That’s a very specific type of institutional trust and process reproducibility that few early-stage players have achieved.

When Lineage talks about islet manufacturing, they’re not claiming superiority today — they’re signaling a credible path to industrialization grounded in real regulatory experience and established differentiation protocols. That’s miles away from academic proof-of-concept work,
OpRegen and islets differ in scale — but the cell-making engine behind both is the same, and that’s the part that investors are watching. Proven manufacturing IP

Jerry

 
Fair point — islet scale-up is an entirely different order of magnitude, no one’s disputing that. But you’re overlooking why 

 is positioned better than most to approach that challenge.

The key advantage isn’t just existing GMP capacity — it’s a validated process-development platform that’s already been audited, scaled, and transferred under a global pharma partnership. That’s a very specific type of institutional trust and process reproducibility that few early-stage players have achieved.

When Lineage talks about islet manufacturing, they’re not claiming superiority today — they’re signaling a credible path to industrialization grounded in real regulatory experience and established differentiation protocols. That’s miles away from academic proof-of-concept work,
OpRegen and islets differ in scale — but the cell-making engine behind both is the same, and that’s the part that investors are watching. Proven manufacturing IP